Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

Ascendiant Capital analyst Edward Woo has maintained a Buy rating on Aytu BioPharma (NASDAQ: AYTU) and raised the price target from $14.5 to $15. This adjustment reflects a positive outlook for the company.